The Life Raft Group and UCSD hosted a three-day event at University of California, San Diego UCSD-Moores Cancer Center from July 13th through July 15th. A GIST Awareness Day (GAD) event took place on July [...]
GIST advocates from around the world gathered in Miami for the annual New Horizons conference. This international meeting was launched by Novartis Oncology in 2003 with the title, “New Horizons in Treating CML and [...]
LRG Board Member John Poss presents Bayer Pharmaceuticals, represented by Laura Reilly, with the Patient Outreach Award for their continued dedication to the research and development of new treatments for GIST. View [...]
The European Commission recently announced that Stivarga (regorafenib) from Bayer has been approved in the European Union (EU) as a third line treatment for GIST.
Coverage of GIST Awareness Day continues with this press release that calls attention to our awareness campaign and our support for the global GIST community.
Stivarga has just been approved in Japan for the treatment of GIST. Keep reading for more information.Official Stivarga Press Release:Bayer HealthCare has received approval from the Japanese authorities (MHLW) for the marketing of Regorafenib (Stivarga) [...]
The Food and Drug Administration, in a much-anticipated announcement for Gastrointestinal Stromal Tumor patients, approved Bayer Pharmaceutical’s drug, Stivarga, for use as a third-line treatment for advanced GIST in February.
The Food and Drug Administration, in a much-anticipated announcement for Gastrointestinal Stromal Tumor patients, has approved Bayer Pharmaceutical's drug, Stivarga, for use as a third-line treatment for advanced GIST.
“It was such a frustrating time. It was awful,” Linda says, recalling how doctors had recommended she give Glaxo-SmithKline’s drug Votrient a shot but was unable to get Jessica’s insurance company to cover it despite appeals documented by GIST specialists.
In our last newsletter, we covered some resources available to you to cover your prescription drugs outside of Medicare, in this last article in the series, we will look at pharmaceutical company assistance.